Episode 12: Tebentafusp-tebn - The Backstory

Type: IndividualFormat: On-demand

Upon completion of this activity, participants will be able to:

  • Articulate the reasoning behind an FDA oncology drug approval.
  • Identify the relevant sections of the drug USPI where information is located.
  • Integrate this information into their clinical practice.

Review video content here.

Time to Complete Activity: 75

Get it

In This Episode:

Timil Patel, MD Medical Oncologist, Division of Oncology 3, Oncology Center of Excellence

Jamie Brewer, MD - Medical Oncologist and Acting Clinical Team Lead, Division of Oncology 3, Office of Oncologic Diseases

Mark Moyer - Senior Vice President, Head of Regulatory Sciences, Immunocore

Richard D. Carvajal, MD - Deputy Physician-in-Chief, Director of Hematology/Oncology, Northwell Health Cancer Institute

Jianan (Carlos) Sheng - Patient and Clinical Trial Participant

Carol Ann Wiggs - Clinical Research Nurse Manager, Duke Cancer Institute

Heather Armbruster, PharmD, BCOP Outpatient Clinical Pharmacy Manager, James Cancer Hospital & Solove Research Institute

Get it